Survival outcomes in POD1UM-303/InterAACT-2: a phase III study of retifanlimab plus carboplatin–paclitaxel in first-line advanced squamous anal cancer

S. Rao, E. Samalin-Scalzi, L. Evesque, M. Ben Abdelghani, F. Morano, A. Roy, L. Dahan, S. Tamberi, A.S. Dhadda, M.G. Zampino, N. Casanova, R. Guimbaud, A. Lievre, J. Maurel, P. Zhang, M.C. Munteanu, M. Jones, C. de la Fouchardiere, A. Takashima, M. Fakih, J. Spano

Open source

DOI: 10.1016/j.annonc.2026.04.016
Published: 2026-08
Container: Annals of Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.annonc.2026.04.016,
  title = {Survival outcomes in POD1UM-303/InterAACT-2: a phase III study of retifanlimab plus carboplatin–paclitaxel in first-line advanced squamous anal cancer},
  author = {S. Rao and E. Samalin-Scalzi and L. Evesque and M. Ben Abdelghani and F. Morano and A. Roy and L. Dahan and S. Tamberi and A.S. Dhadda and M.G. Zampino and N. Casanova and R. Guimbaud and A. Lievre and J. Maurel and P. Zhang and M.C. Munteanu and M. Jones and C. de la Fouchardiere and A. Takashima and M. Fakih and J. Spano},
  year = {2026},
  journal = {Annals of Oncology},
  doi = {10.1016/j.annonc.2026.04.016},
  url = {https://doi.org/10.1016/j.annonc.2026.04.016}
}

RIS

TY  - JOUR
TI  - Survival outcomes in POD1UM-303/InterAACT-2: a phase III study of retifanlimab plus carboplatin–paclitaxel in first-line advanced squamous anal cancer
AU  - S. Rao
AU  - E. Samalin-Scalzi
AU  - L. Evesque
AU  - M. Ben Abdelghani
AU  - F. Morano
AU  - A. Roy
AU  - L. Dahan
AU  - S. Tamberi
AU  - A.S. Dhadda
AU  - M.G. Zampino
AU  - N. Casanova
AU  - R. Guimbaud
AU  - A. Lievre
AU  - J. Maurel
AU  - P. Zhang
AU  - M.C. Munteanu
AU  - M. Jones
AU  - C. de la Fouchardiere
AU  - A. Takashima
AU  - M. Fakih
AU  - J. Spano
PY  - 2026
JO  - Annals of Oncology
DO  - 10.1016/j.annonc.2026.04.016
UR  - https://doi.org/10.1016/j.annonc.2026.04.016
ER  -

APA

Rao, S., Samalin-Scalzi, E., Evesque, L., Abdelghani, M. B., Morano, F., Roy, A., Dahan, L., Tamberi, S., Dhadda, A., Zampino, M., Casanova, N., Guimbaud, R., Lievre, A., Maurel, J., Zhang, P., Munteanu, M., Jones, M., Fouchardiere, C. D. L., Takashima, A., Fakih, M., & Spano, J. (2026). Survival outcomes in POD1UM-303/InterAACT-2: a phase III study of retifanlimab plus carboplatin–paclitaxel in first-line advanced squamous anal cancer. Annals of Oncology. https://doi.org/10.1016/j.annonc.2026.04.016

Source records

crossref · retrieved 2026-09-26T15:52:27.933Z